Cargando…

Dissection of two routes to naïve pluripotency using different kinase inhibitors

Embryonic stem cells (ESCs) can be maintained in the naïve state through inhibition of Mek1/2 and Gsk3 (2i). A relevant effect of 2i is the inhibition of Cdk8/19, which are negative regulators of the Mediator complex, responsible for the activity of enhancers. Inhibition of Cdk8/19 (Cdk8/19i) stimul...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Val, Ana, Lynch, Cian J., Calvo, Isabel, Ximénez-Embún, Pilar, Garcia, Fernando, Zarzuela, Eduardo, Serrano, Manuel, Munoz, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994667/
https://www.ncbi.nlm.nih.gov/pubmed/33767186
http://dx.doi.org/10.1038/s41467-021-22181-5
_version_ 1783669801723363328
author Martinez-Val, Ana
Lynch, Cian J.
Calvo, Isabel
Ximénez-Embún, Pilar
Garcia, Fernando
Zarzuela, Eduardo
Serrano, Manuel
Munoz, Javier
author_facet Martinez-Val, Ana
Lynch, Cian J.
Calvo, Isabel
Ximénez-Embún, Pilar
Garcia, Fernando
Zarzuela, Eduardo
Serrano, Manuel
Munoz, Javier
author_sort Martinez-Val, Ana
collection PubMed
description Embryonic stem cells (ESCs) can be maintained in the naïve state through inhibition of Mek1/2 and Gsk3 (2i). A relevant effect of 2i is the inhibition of Cdk8/19, which are negative regulators of the Mediator complex, responsible for the activity of enhancers. Inhibition of Cdk8/19 (Cdk8/19i) stimulates enhancers and, similar to 2i, stabilizes ESCs in the naïve state. Here, we use mass spectrometry to describe the molecular events (phosphoproteome, proteome, and metabolome) triggered by 2i and Cdk8/19i on ESCs. Our data reveal widespread commonalities between these two treatments, suggesting overlapping processes. We find that post-transcriptional de-repression by both 2i and Cdk8/19i might support the mitochondrial capacity of naive cells. However, proteome reprogramming in each treatment is achieved by different mechanisms. Cdk8/19i acts directly on the transcriptional machinery, activating key identity genes to promote the naïve program. In contrast, 2i stabilizes the naïve circuitry through, in part, de-phosphorylation of downstream transcriptional effectors.
format Online
Article
Text
id pubmed-7994667
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79946672021-04-16 Dissection of two routes to naïve pluripotency using different kinase inhibitors Martinez-Val, Ana Lynch, Cian J. Calvo, Isabel Ximénez-Embún, Pilar Garcia, Fernando Zarzuela, Eduardo Serrano, Manuel Munoz, Javier Nat Commun Article Embryonic stem cells (ESCs) can be maintained in the naïve state through inhibition of Mek1/2 and Gsk3 (2i). A relevant effect of 2i is the inhibition of Cdk8/19, which are negative regulators of the Mediator complex, responsible for the activity of enhancers. Inhibition of Cdk8/19 (Cdk8/19i) stimulates enhancers and, similar to 2i, stabilizes ESCs in the naïve state. Here, we use mass spectrometry to describe the molecular events (phosphoproteome, proteome, and metabolome) triggered by 2i and Cdk8/19i on ESCs. Our data reveal widespread commonalities between these two treatments, suggesting overlapping processes. We find that post-transcriptional de-repression by both 2i and Cdk8/19i might support the mitochondrial capacity of naive cells. However, proteome reprogramming in each treatment is achieved by different mechanisms. Cdk8/19i acts directly on the transcriptional machinery, activating key identity genes to promote the naïve program. In contrast, 2i stabilizes the naïve circuitry through, in part, de-phosphorylation of downstream transcriptional effectors. Nature Publishing Group UK 2021-03-25 /pmc/articles/PMC7994667/ /pubmed/33767186 http://dx.doi.org/10.1038/s41467-021-22181-5 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Martinez-Val, Ana
Lynch, Cian J.
Calvo, Isabel
Ximénez-Embún, Pilar
Garcia, Fernando
Zarzuela, Eduardo
Serrano, Manuel
Munoz, Javier
Dissection of two routes to naïve pluripotency using different kinase inhibitors
title Dissection of two routes to naïve pluripotency using different kinase inhibitors
title_full Dissection of two routes to naïve pluripotency using different kinase inhibitors
title_fullStr Dissection of two routes to naïve pluripotency using different kinase inhibitors
title_full_unstemmed Dissection of two routes to naïve pluripotency using different kinase inhibitors
title_short Dissection of two routes to naïve pluripotency using different kinase inhibitors
title_sort dissection of two routes to naïve pluripotency using different kinase inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994667/
https://www.ncbi.nlm.nih.gov/pubmed/33767186
http://dx.doi.org/10.1038/s41467-021-22181-5
work_keys_str_mv AT martinezvalana dissectionoftworoutestonaivepluripotencyusingdifferentkinaseinhibitors
AT lynchcianj dissectionoftworoutestonaivepluripotencyusingdifferentkinaseinhibitors
AT calvoisabel dissectionoftworoutestonaivepluripotencyusingdifferentkinaseinhibitors
AT ximenezembunpilar dissectionoftworoutestonaivepluripotencyusingdifferentkinaseinhibitors
AT garciafernando dissectionoftworoutestonaivepluripotencyusingdifferentkinaseinhibitors
AT zarzuelaeduardo dissectionoftworoutestonaivepluripotencyusingdifferentkinaseinhibitors
AT serranomanuel dissectionoftworoutestonaivepluripotencyusingdifferentkinaseinhibitors
AT munozjavier dissectionoftworoutestonaivepluripotencyusingdifferentkinaseinhibitors